G. Walmsley Graham - 19 Sep 2022 Form 4/A - Amendment Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
19 Sep 2022
Net transactions value
+$15,440,000
Form type
4/A - Amendment
Filing time
15 Jun 2023, 21:26:16 UTC
Date Of Original Report
23 May 2023
Previous filing
27 Jun 2022
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Purchase $10,400,000 +400,000 $26.00 400,000 19 Sep 2022 See Footnote F1, F2
transaction AKRO Common Stock Purchase $5,040,000 +120,000 +30% $42.00 520,000 19 May 2023 See Footnote F2
holding AKRO Common Stock 2,168 19 Sep 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 amendment is being filed solely to correct the original Form 4 filed on May 23, 2023, which inadvertently included the incorrect transaction date of September 19, 2023, due to a clerical error. This amendment corrects the date of the transaction to September 19, 2022.
F2 The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.